Research shows that combining cabozantinib with the mTOR inhibitor, rapamycin, effectively counters resistance in HCC by halting cell proliferation, migration, and invasion, marking a significant advance in HCC therapy [39]. This evidence concerns the gene MTOR and hepatocellular carcinoma.